Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 2/20 | 0.66 |
| ▸ | ALPI | P09923 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | XIAP | P98170 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.54 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.54 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.54 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.54 |
| ▸ | NOS1 | P29475 | 2/20 | 0.54 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | GSR | P00390 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.51 |
| ▸ | KIF11 | P52732 | 3/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28465699 | 1.00 | GRIK1 (0.66) | GRIK1ALPIPKMPTGS1XIAP | |
| SCHEMBL372365 | 1.00 | GRIK1 (0.66) | GRIK1ALPIPKMPTGS1XIAP | |
| SCHEMBL17686506 | 0.98 | GRIK1 (0.64) | GRIK1ALPIPKMPTGS1XIAP | |
| SCHEMBL3664379 | 0.98 | GRIK1 (0.64) | GRIK1ALPIPKMPTGS1XIAP | |
| SCHEMBL28469566 | 0.98 | GRIK1 (0.64) | GRIK1ALPIPKMPTGS1XIAP | |
| SCHEMBL24816430 | 0.98 | GRIK1 (0.64) | GRIK1ALPIPKMPTGS1XIAP | |
| SCHEMBL23176817 | 0.98 | GRIK1 (0.64) | GRIK1ALPIPKMPTGS1XIAP | |
| SCHEMBL17686507 | 0.98 | GRIK1 (0.64) | GRIK1ALPIPKMPTGS1XIAP | |
| Hydrochloric Acid SCHEMBL27330363 | 0.98 | GRIK1 (0.64) | GRIK1ALPIPKMPTGS1XIAP | |
| SCHEMBL3664561 | 0.98 | GRIK1 (0.64) | GRIK1ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305900-B1 | ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIES | NUEVOLUTION AS (DK) | 2021-07-21 | — | — | EP | disclosed |
| US-8524657-B2 | Peptidic compounds | UNIVERSITY OF WOLLONGONG (AU) | 2013-09-03 | — | — | US | disclosed |
| EP-1836159-B1 | Antibiotic binaphthyl derivatives | UNIV WOLLONGONG (AU) | 2013-04-10 | — | — | EP | disclosed |
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2011-12-22 | — | — | US | disclosed |
| EP-2199300-A2 | Peptidic compounds | The University Of Wollongong (AU) | 2010-06-23 | — | — | EP | disclosed |
| EP-1836159-A4 | PEPTIDIC COMPOUNDS | UNIV WOLLONGONG (AU) | 2009-02-25 | — | — | EP | disclosed |
| EP-1836159-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2007-09-26 | — | — | EP | disclosed |
| EP-1103560-B1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO LTD (JP) | 2006-12-27 | — | — | EP | disclosed |
| WO-2006074501-A1 | PEPTIDIC COMPOUNDS | UNIVERSITY OF WOLLONGONG (AU) | 2006-07-20 | — | — | WO | disclosed |
| US-6410576-B1 | ANTIINFLAMMATORY AGENTS; CARDIOVASCULAR DISORDERS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-06-25 | — | — | US | disclosed |
| EP-1103560-A1 | NOVEL THIAZOLIDINE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-05-30 | — | — | EP | disclosed |
| CN-1032308-C | Process for preparing optically active 2-oxoimidazolidine derivatives | TANABE SEIYAKU CO (JP) | 1996-07-17 | — | — | CN | disclosed |
| CN-1043705-A | The method for preparing opticity 2-oxo-imidazole alkane derivatives | TANABE SEIYAKU CO (JP) | 1990-07-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312875-A1 | PEPTIDIC COMPOUNDS | VIP, NGLY1, FURIN | GRIK1 4636/4885ALPI 2406/4885PKM 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.